A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints
Advanced Science · 2026-11 · 13 (63)
DOI: 10.1002/advs.77339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 21.08.2026. Verfasst von Wang Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Metabolism, and School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic…. Hauptthemen laut MEDLINE: Complementarity Determining Regions, Antibody Diversity, V(D)J Recombination, Protein Engineering. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Shanghai Municipal Science and Technology Major Project, and the Project of State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University.
Abstract (Originalsprache)
Antibody junctional diversity in jawed vertebrates arose from RAG transposon domestication, generating CDR3‐focused V(D)J recombination with lymphocyte specificity—a constrained system limiting engineered antibody diversity. To overcome these limitations, we developed ARESEC ( A ntibody R eprogram and E xpression S ystem in E ngineered C ells), a synthetic platform that enables programmable V(D)J recombination in non‐lymphoid HEK293T cells. Through engineered recombination signal sequences (RSS) and optimized RAG1/2 expression, ARESEC enables RSS‐guided DNA recombination across all three complementarity‐determining regions (CDR1/2/3). Co‐expression of terminal deoxynucleotidyl transferase (TdT) enhanced junctional sequence diversity by 41.5%–86.3% across 3 CDRs. The platform enables native IgG production by coupling mammalian surface display with FACS‐based functional screening. Using clinical‐grade antibodies (Nivolumab and Durvalumab) as high‐affinity starting scaffolds, we achieved further efficient affinity maturation through focused CDR diversification (library complexity >10 3 ). From these diversification libraries, we identified optimized variants including the anti‐PD‐L1 Dur1 with 2.01‐fold enhanced binding, demonstrating the system's capacity for rapid antibody optimization from minimal diversity sampling. Collectively, ARESEC establishes a synthetic platform that transcends natural V(D)J constraints, generating multi‐CDR diversification in non‐lymphoid cells to enable rapid discovery of affinity‐matured antibodies, effectively bridging immune evolution with modern antibody engineering demands.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Microbial Metabolism, and School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
- Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
ORCID-Profile: Wang Liu
Förderung
- National Key Research and Development Program of China
- Shanghai Municipal Science and Technology Major Project, and the Project of State Key Laboratory of Microbial Metabolism, Shanghai Jiao Tong University
Zitieren
APA
Liu, W., Yang, J., Zhang, Y., & Xue, X. (2026). A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints. Advanced Science, 13(63). https://doi.org/10.1002/advs.77339
Vancouver
Liu W, Yang J, Zhang Y, Xue X. A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints. Advanced Science. 2026;13(63). doi:10.1002/advs.77339
BibTeX
@article{Liu2026,
author = {Liu, Wang and Yang, Jun and Zhang, Yuhang and Xue, Xiaoli},
title = {A Synthetic Platform for Antibody Junctional Diversification Beyond Natural Constraints},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {63},
doi = {10.1002/advs.77339}
}
EUVIMED